Tocilizumab (Actemra)

Provider Order Form rev. 3/25/2022

IVX HEALTH

PATIENT INFORMATION

Date: Patient Name: DOB:

ICD-10 code (required): ICD-10 description:

☐ NKDA Allergies: Weight lbs/kg:

Patient Status: ☐ New to Therapy ☐ Continuing Therapy Last Treatment Date: Next Due Date:

PROVIDER INFORMATION

Referral Coordinator Name: Referral Coordinator Email:

Ordering Provider: Provider NPI:

Referring Practice Name: Phone: Fax:

Practice Address: City: State: Zip Code:

NURSING

☑ TB status and date (results) _____

☑ Provide nursing care per IVX Nursing Procedures, including reaction management and post-procedure observation
NOTE: IVX Adverse Reaction Management Protocol available for review at www.ivxhealth.com/forms (version 09.07.2021)

LABORATORY ORDERS

☑ CBC ☐ at each dose ☑ every _____
☐ CMP ☐ at each dose ☐ every _____
☐ CRP ☐ at each dose ☐ every _____
☐ Other: _____

PRE-MEDICATION ORDERS

☐ acetaminophen (Tylenol) ☐ 500mg / ☐ 650mg / ☐ 1000mg PO
☐ cetirizine (Zyrtec) 10mg PO
☐ loratadine (Claritin) 10mg PO
☐ diphenhydramine (Benadryl) ☐ 25mg / ☐ 50mg ☐ PO / ☐ IV
☐ methylprednisolone (Solu-Medrol) ☐ 40mg / ☐ 125mg IV
☐ hydrocortisone (Solu-Cortef) ☐ 100mg IV
☐ Other: _____
Dose: _____ Route: _____
Frequency: _____

SPECIAL INSTRUCTIONS

THERAPY ADMINISTRATION

☐ **Tocilizumab** (Actemra) in 100ml 0.9% sodium chloride for patient weight >30kg or 50ml 0.9% sodium chloride for patient weight <30kg, intravenous infusion over one hour
- Dose: ☐ 4mg/kg / ☐ 8mg/kg / ☐ 10mg/kg / ☐ 12mg/kg / ☐ _____mg/kg

☐ round up to nearest whole vial
☐ give exact dose
- Frequency: ☐ every 2 weeks / ☐ every 4 weeks / ☐ other: _____
- Route: ☑ intravenous
- Infuse over 1 hour

☑ Flush with 0.9% sodium chloride at the completion of infusion

☐ **Tocilizumab** (Actemra) injection
- Dose: ☐ 162mg / ☐ _____mg
- Frequency: ☐ weekly / ☐ every 2 weeks / ☐ every 3 weeks / ☐ other: _____
- Route: ☑ subcutaneous

☐ Patient required to stay for 30-min observation post procedure
☐ Patient is NOT required to stay for observation time
☐ Refills: ☐ Zero / ☐ for 12 months / ☐ _____
(if not indicated order will expire one year from date signed)

Perform test for latent TB; if positive, start treatment for TB prior to starting ACTEMRA. Monitor all patients for active TB during treatment, even if initial latent TB test is negative.

It is recommended that ACTEMRA not be initiated in patients with an absolute neutrophil count (ANC) below 2000 per mm3, platelet count below 100,000 per mm3, or who have ALT or AST above 1.5 times the upper limit of normal (ULN).

Laboratory monitoring—recommended due to potential consequences of treatment-related changes in neutrophils, platelets, lipids, and liver function tests.

Provider Name (Print) **Provider Signature** **Date**

FAX NUMBERS

☐ **BAY AREA: 844-889-0275**
☐ **CHARLOTTE: 336-663-0143**
☐ **CINCINNATI: 844-946-0868**
☐ **CHICAGO: 312-253-7244**
☐ **COLUMBUS: 844-627-2675**
☐ **DAYTONA: 386-259-6096**
☐ **HARRISBURG: 844-859-4235**
☐ **HARTFORD: 860-955-1532**
☐ **INDIANAPOLIS: 844-983-2028**
☐ **JACKSONVILLE: 904-212-2338**
☐ **KANSAS CITY: 844-900-1292**
☐ **ORLANDO: 844-946-0867**
☐ **PALM BEACH: 561-768-9044**
☐ **PHILADELPHIA: 844-820-9641**
☐ **RALEIGH: 919-287-2551**
☐ **SARASOTA: 941-870-6550**
☐ **SOUTHWEST FL: 813-283-9144**
☐ **TAMPA: 844-946-0849**
☐ **WEST TN/AR: 888-615-1445**
☐ **MIDDLE TN: 888-615-1445**
☐ **EAST TN: 615-425-7427**